This week’s edition of the Weekender is about new drug approvals, New Jersey’s role in the launch of the Congressional Life Science Caucus, important partnerships forging medical innovation and New Jersey’s fastest growing companies…
Congressman Leonard Lance recently announced the creation of the Congressional Life Science Caucus that will serve as a bipartisan working group. The Caucus will educate members of Congress, federal stakeholders and other industries on the legislative goals of the life science sector – a major jobs engine in the State.
It’s an exciting time for BioNJ Member Bristol-Myers Squibb Company with the announcement of the FDA approval of Opdivo (nivolumab) injection, for intravenous use, as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Additionally, BMS and Abbvie received FDA approval of Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy with Revlimid® (lenalidomide) and dexamethasone (ERd) in patients who have received one to three prior therapies.
BioNJ Member Eli Lilly and Company announced that the FDA has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with metastatic squamous non-small cell lung cancer.
Meanwhile, BioNJ Member Allergan and Rugen Therapeutics announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive Disorders (OCD). Allergan sought out this collaboration due to its “passion and willingness to invest in people with ASD and their families and to identify ground-breaking therapeutic modalities to help them”.
Congratulations to BioNJ Members ADMA Biologics, Inc. and GENEWIZ for making NJBIZ’s list of New Jersey’s 50 Fastest Growing Companies!
Click here to read this week’s Weekender.